Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly EBITDA Margin of 17.24% for Q1 2026, up 8807.0% year-on-year from 0.19% in Q1 2025, and up 67.02% on a QoQ basis from 10.32% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 18 years of EBITDA Margin data on file, last reported at 17.24% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 8807.0% year-over-year to 17.24%; the trailing twelve-month figure through Mar 2026 stood at 12.01% (up 2552.0% YoY), and the FY2025 full-year result was 8.84%, up 2170.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 17.24%, up from 10.32% in the prior quarter.
- Across five years, EBITDA Margin topped out at 20.76% in Q3 2025 and bottomed at 154.17% in Q3 2022.
- The 5-year median for EBITDA Margin is 20.31% (2024), against an average of 40.49%.
- The widest annual swing landed in 2023, when EBITDA Margin jumped 17449 bps; it then sank 5676 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 62.19% in 2022, then jumped by 53 bps to 29.32% in 2023, then surged by 46 bps to 15.76% in 2024, then soared by 166 bps to 10.32% in 2025, then jumped by 67 bps to 17.24% in 2026.
- The last three EBITDA Margin figures came in at 17.24% (Q1 2026), 10.32% (Q4 2025), and 20.76% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.24% |
| Dec 31, 2025 | 10.32% |
| Sep 30, 2025 | 20.76% |
| Jun 30, 2025 | -7.59% |
| Mar 31, 2025 | -70.83% |
| Dec 31, 2024 | -15.76% |
| Sep 30, 2024 | -20.31% |
| Jun 30, 2024 | -3.72% |
| Mar 31, 2024 | -14.07% |
| Dec 31, 2023 | -29.32% |
| Sep 30, 2023 | 20.32% |
| Jun 30, 2023 | -85.95% |
| Mar 31, 2023 | -52.80% |
| Dec 31, 2022 | -62.19% |
| Sep 30, 2022 | -154.17% |
| Jun 30, 2022 | -125.24% |
| Mar 31, 2022 | -114.95% |
| Dec 31, 2021 | -99.60% |
| Sep 30, 2021 | -108.01% |
| Jun 30, 2021 | -85.66% |
| Mar 31, 2021 | -108.91% |
| Dec 31, 2020 | -152.83% |
| Sep 30, 2020 | -204.42% |
| Jun 30, 2020 | -173.51% |
| Mar 31, 2020 | -178.70% |
| Dec 31, 2019 | -388.29% |
| Sep 30, 2019 | -295.56% |
| Jun 30, 2019 | -497.52% |
| Mar 31, 2019 | -545.31% |
| Dec 31, 2018 | -1,004.43% |
| Sep 30, 2018 | -11,835.04% |
| Jun 30, 2018 | -543.40% |
| Mar 31, 2018 | -646.76% |
| Dec 31, 2017 | -376.86% |
| Sep 30, 2017 | -717.82% |
| Jun 30, 2017 | -744.11% |
| Mar 31, 2017 | -567.92% |
| Dec 31, 2016 | -679.48% |
| Sep 30, 2016 | -758.57% |
| Jun 30, 2016 | -1,256.33% |
| Mar 31, 2016 | -1,584.13% |
| Dec 31, 2015 | -1,047.98% |
| Sep 30, 2015 | -1,625.13% |
| Jun 30, 2015 | -1,213.66% |
| Mar 31, 2015 | -254.38% |
| Dec 31, 2014 | 50.74% |
| Sep 30, 2014 | -462.87% |
| Jun 30, 2014 | -645.94% |
| Mar 31, 2014 | -2,968.34% |
| Dec 31, 2013 | -367.00% |
| Sep 30, 2013 | -340.87% |
| Jun 30, 2013 | -125.01% |
| Mar 31, 2013 | -20.67% |
| Dec 31, 2012 | -548.96% |
| Sep 30, 2012 | -115.35% |
| Jun 30, 2012 | -62.16% |
| Mar 31, 2012 | -54.60% |
| Dec 31, 2011 | -69.99% |
| Sep 30, 2011 | -63.21% |
| Jun 30, 2011 | -68.17% |
| Mar 31, 2011 | -81.43% |
| Dec 31, 2010 | -35.41% |
| Sep 30, 2010 | -34.80% |
| Jun 30, 2010 | -53.23% |
| Mar 31, 2010 | -49.73% |
| Dec 31, 2009 | -33.67% |
| Sep 30, 2009 | -36.87% |
| Jun 30, 2009 | -88.22% |